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Preterm birth (PTB) complications are the leading cause of long-term
morbidity and mortality in children. By using whole blood samples,
we integrated whole-genome sequencing (WGS), RNA sequencing
(RNA-seq), and DNA methylation data for 270 PTB and 521 control
families. We analyzed this combined dataset to identify genomic
variants associated with PTB and secondary analyses to identify
variants associated with very early PTB (VEPTB) as well as other
subcategories of disease that may contribute to PTB. We identified
differentially expressed genes (DEGs) and methylated genomic loci
and performed expression and methylation quantitative trait loci
analyses to link genomic variants to these expression and methyl-
ation changes. We performed enrichment tests to identify overlaps
between new and known PTB candidate gene systems. We identi-
fied 160 significant genomic variants associated with PTB-related
phenotypes. The most significant variants, DEGs, and differentially
methylated loci were associated with VEPTB. Integration of all data
types identified a set of 72 candidate biomarker genes for VEPTB,
encompassing genes and those previously associated with PTB.
Notably, PTB-associated genes RAB31 and RBPJ were identified by
all three data types (WGS, RNA-seq, and methylation). Pathways
associated with VEPTB include EGFR and prolactin signaling path-
ways, inflammation- and immunity-related pathways, chemokine
signaling, IFN-γ signaling, and Notch1 signaling. Progress in identify-
ing molecular components of a complex disease is aided by inte-
grated analyses of multiple molecular data types and clinical data.
With these data, and by stratifying PTB by subphenotype, we have
identified associations between VEPTB and the underlying biology.
preterm birth | whole genome sequencing | family trios |
integrative computational analysis | genomic variants
Preterm birth (PTB) is defined as a live birth occurring before37 weeks (wk) of completed gestation. Every year, ∼15 million
infants worldwide are born preterm (1). PTB-related complications
result in 1 million deaths yearly (2); surviving preterm infants
have a significantly increased risk of developmental and medical
disabilities (3). PTB is the endpoint of a complex process spanning
fetal development and is influenced by fetal and maternal factors
(4–8). In approximately half of PTB cases, there are no apparent
known risk factors; in the other half, known risk factors or clinical
antecedents such as preeclampsia lead to early delivery (9–11).
There is a racial disparity in preterm and previable birth rates that
may result from genetic, epidemiological, or other factors (12–14).
PTB heritability is estimated to be 15–35% based on twin and
family studies (15–17). Genomewide association studies (GWASs)
and candidate gene studies have implicated genes (18–21) that
illuminate several systems involved in PTB, including immune
response, inflammation, coagulation factors, and connective
tissue remodeling (19). The most comprehensive GWAS performed
to date for PTB identified replicable loci in six genes (EBF1,
EEFSEC, AGTR2, WNT4, ADCY5 and RAP2C) associated
with gestational duration, with three of these six genes (EBF1,
EEFSEC and AGTR2) strongly associated with PTB in a European
ancestry cohort of 43,568 women (22). Furthermore, Zhang et al.
(22) determined that common maternal SNPs could explain 23% of
the phenotypic variance in PTB observed in this cohort, suggesting
that other sources that could explain PTB phenotypic variation need
to be investigated further. Gene expression and DNA methylation
studies have also identified biomarkers (23–25), often in the
same systems illuminated by the candidate genes.
Current knowledge of PTB environmental and genetic factors is
incomplete, and little is known of the strength of these factors or
how they interact. Integrative systems biology approaches can be
applied to overcome the challenges in studying pregnancy-related
complications (26). To characterize the molecular mechanisms that
may be altered in PTB, we integrated molecular and clinical data for
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270 PTB and 521 control families. We performed whole-genome
sequencing (WGS) of maternal, paternal, and neonatal DNA for
each family trio. We carried out mRNA sequencing (RNA-seq) and
miRNA sequencing and DNA methylation profiling of maternal
whole blood. We employed an integrative approach to characterize
PTB at the genomic, transcriptomic, and epigenomic levels. We
identified dozens of PTB candidate genes and provide further evi-
dence for previously reported PTB genes and networks. This type of
approach can be used to analyze other etiologically complex con-
ditions for which very large cohorts are not yet available.
Results
Study Population. The study population consisted of 791 family
trios (father, mother, and newborn), of which 270 involved de-
liveries of live births before 37 wk of gestation (Fig. 1A). Families
were recruited at the time of delivery at the Inova Fairfax
Medical Center from 2011 to 2013. The recruitment was performed
to enrich for cases of PTB, early PTB (EPTB), and very early PTB
(VETBP). Clinical information was obtained by interview, electronic
medical records (EMRs), and self-reported data from a study-
specific case report form. Because of potential biases in self-
reported ancestry, we computed admixture coefficients from
WGS data by using the 1000 Genomes reference ancestries (27).
The maternal cohort included African (n = 43), East Asian (n =
75), European (n = 377), admixed American (n = 127), and mixed
individuals in cases in which inferred admixture coefficients were
inconclusive (n = 169; Fig. 1B).
PTB-Related Clinical Phenotypes. For our primary analysis, we tested
associations with the PTB phenotype (gestation <37 wk) by using
all full-term births (FTBs; gestation ≥37 and <42 wk) as controls.
We defined eight additional phenotypes (Table 1) for secondary
case-control analyses: (i) VEPTB <28 wk, (ii) EPTB <34 wk (in-
cluding VEPTB cases), (iii) premature rupture of membranes
(PROM), (iv) preeclampsia (encompassing eclampsia), (v) placenta-
related (e.g., placental previa/abruption), (vi) uterine-related (e.g.,
uterine anomalies and endometriosis), (vii) cervix-related, and (viii)
idiopathic (no evidence of infection, cervical insufficiency, uterine
abnormalities, placentation abnormalities, or maternal disease
known to cause premature delivery). These phenotypes are not
mutually exclusive. Cases and controls for each secondary analysis
are depicted in SI Appendix, Fig. S1. It is important to note that the
case and control definitions refer to an individual such as the
mother or newborn or refer to the family trio. This highlights a
unique challenge in analyzing disorders that affect pregnancy, in
which multiple persons or a group of persons (i.e., family trio) can be
viewed as the “case” in an analysis. Detailed descriptions of these
phenotypes are given in the SI Appendix.
Genomewide Statistical Tests Identify Candidate PTB Genes.WGS was
performed by Complete Genomics on 791 mothers, 791 fathers,
and 839 newborns. In total, there were 784 complete family trios,
i.e., the genomes from the mother, father, and newborn were
successfully sequenced. Sixty-three families had twins and one
family had triplets. For our analyses, only one newborn was
(randomly) chosen from each multiple-birth family. After filtering
for quality and minor allele frequency (MAF), the total number of
variants with MAF ≥ 1% across all individuals was 6,987,906
(Dataset S1). We applied two complementary statistical tests for
genomic associations: EIGENSTRAT (28) and the family-based
association test (FBAT) (29). EIGENSTRAT is an individual-
based test that corrects for population stratification. FBAT is ro-
bust to population stratification and quantifies the disequilibrium
of transmission of alleles from parents to offspring. We performed
Fig. 1. Study overview. (A) Graphical overview of the study described in this report. We collected peripheral blood samples from 791 family trios, of which
270 represented PTBs. We carried out WGS of DNA for each member of the family trio, i.e., the father, mother, and newborn. We profiled mRNA and miRNA
expression by using RNA-seq as well as DNA methylation in the maternal samples. Extensive clinical information was captured by using EMRs and study-
specific patient surveys. All these data were integrated in an analytical framework to characterize the genomic and molecular associations with PTB and
related clinical phenotypes. (B) Summary of distribution of family trios across clinical phenotypes and ancestries broken down by PTB categories based on
gestational age. Molecular data indicate the number of maternal samples profiled for DNA methylation and mRNA and miRNA expression. Numbers cited
indicate samples that passed stringent quality-control criteria for inclusion in this report.
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EIGENSTRAT for each of the nine phenotypes (Table 1) and
each of the three sample groups: mothers, fathers, and newborns.
We performed FBAT under the additive genetic model for each
of the nine phenotypes separately. FBAT was run for the 784 family
trios with complete WGS. To avoid inflated P values caused by
small sample sizes, we did not test rare variants (MAF < 5%) for
FBAT and required at least 10 cases and 10 controls with non-
reference alleles for EIGENSTRAT. Further details are provided
in SI Appendix.
When considering PTB as a single cohort (our primary analysis),
we found no significant variant associations by EIGENSTRAT or
FBAT. However, application of these tests in our eight secondary
analyses (EPTB, VEPTB, PROM, preeclampsia, placenta-related,
uterine-related, cervix-related, and idiopathic) identified 160 vari-
ants with moderately significant associations at an uncorrected
P value cutoff of 1 × 10−8 (Table 1 and Dataset S2). Of these var-
iants, 27 were discovered by using FBAT and 133 were discov-
ered by using EIGENSTRAT; we found no overlap between
significant EIGENSTRAT and FBAT variants for any phenotype,
but several identified variants showed associations across multiple
phenotypes (Dataset S3). Of the 160 variants, 66 were within genes,
none of which led to coding changes, and 94 were intergenic,
including 9 variants in long intergenic noncoding RNAs. Impor-
tantly, we found no highly significant variants, but many moderately
significant variants, as can be seen by the large number of small
peaks in the corresponding Manhattan plots (Fig. 2A and SI Ap-
pendix, Fig. S2). Notably, 48 were associated with VEPTB and EPTB.
For some variants, including one in the ST6GALNAC3 gene, we
Table 1. Summary of genomic association tests across clinical phenotypes
Clinical phenotype
No. of
Cases
No. of
Controls
FBAT EIGENSTRAT
Family trio Father Mother Newborn
No. genes No. igr No. genes No. igr No. genes No. igr No. genes No. igr
Preterm 270 521 — — — — — — — —
Early preterm 117 521 1 1 — — 1 1 — —
Very early preterm 44 521 3 1 1 2 3 6 3 5
PROM 107 684 3 1 1 — 1 — — —
Pre-eclampsia 50 741 11 5 3 4 7 5 6 10
Idiopathic PTB 103 520 — 1 — — — — — —
Placenta-related 114 677 2 1 1 — — — 1 1
Uterine-related 45 746 9 6 1 5 2 4 7 7
Cervix-related 72 719 4 3 1 2 — 2 2 1
Number of statistically significant variants associated with a given clinical phenotype at the P value threshold 10−8 for the family-
based test FBAT and the EIGENSTRAT test, which was performed for the maternal, paternal, and neonatal genomes separately. igr,
intergenic region.
Fig. 2. Manhattan plot of genomic associations in PTB. (A) Genomewide significance values (−log10 P values) for all variants tested for association with PTB,
EPTB, and VEPTB. Association tests were performed by using EIGENSTRAT on the paternal, maternal, or neonatal genomes separately. The green horizontal
line represents the global P value threshold of 10−8. Stacked points represent variants within close proximity of one another. (B) Zoomed-in view of chr1 from
70,000,000 bps to 80,000,000 bps, which includes the ST6GALNAC3 locus.
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observed progressively increasing statistical significance for the PTB,
EPTB, and VEPTB phenotypes (Fig. 2B). Fifty-two variants were
associated with preeclampsia, 7 with PROM, and 1 with idiopathic
PTB; 6 were placenta-related, 59 were uterine-related, and 17 were
cervix-related (Table 1 and Dataset S2). Of the associations iden-
tified by EIGENSTRAT, 40 were to variants in the maternal
genome, 57 to the newborn genome, and 36 to the paternal ge-
nome. These sets of significant variants were mutually exclusive
among the maternal, newborn, and paternal cohorts. After collapsing
correlated and nearby variants, i.e., those that are in linkage
disequilibrium, we identified variants in 8, 19, and 14 genes from
the paternal, newborn, and maternal genomes, respectively (Table 1).
These results are consistent with a larger role for the maternal
genome in PTB (7), as well as a role for the fetal genome (with
paternal contributions). These trends are maintained when an-
alyzing the variants at higher or lower levels of statistical signifi-
cance (Dataset S2). The maternal and paternal contributions are
corroborated by FBAT analysis, which demonstrated significant
over- or undertransmission of nonreference alleles from mothers
and fathers to their prematurely born offspring. At a less stringent
level of statistical significance, i.e., a false discovery rate (FDR) <
10%, our analyses reproduced many reported PTB gene associa-
tions, e.g., AGT, COL5A2, CRHR2, FLT1, MMP2, and NAT1
(Dataset S4). Moreover, the genes identified at FDR < 10% were
enriched in published lists of PTB genes (Dataset S5). We also
detected associations, such as a variant in PIN4 that was associated
with EPTB and VETPB according to FBAT (P = 1.2 × 10−9 and
P = 2.5 × 10−13, respectively). Although PIN4 has already been
associated with human spontaneous labor without histologic cho-
rioamnionitis based on gene-expression studies (30), genomic
correlations were not previously identified.
To validate significant findings, we used an independent cohort
of more than 1,300 family trios ascertained through the First 1,000
Days of Life Study (31). We used the validation cohort to specifically
test the significant variants. In this cohort, we observed a small
number of variants with statistical significance (FDR < 10%). A
variant in IFN Lambda Receptor 1 (IFNLR1) showed a partic-
ularly strong association with the PTB phenotype. The details of
this validation study are included in SI Appendix, Supplementary
Note 1 and Fig. S3 and Datasets S6–S8.
Statistical Tests for Single-Gestation Families Highlight Variability in
Genomic Associations but Confirm Strong Hits. Our study population
included families from different ancestries and with various known
risk factors of PTB. Of these factors, multiple-gestation pregnancy is
well known to be strongly related to gestational age, i.e., spontaneous
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Fig. 3. Genomic associations when excluding multiple-gestation families. (A) Bar plot showing the distribution of single- and multiple-gestation families
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PTB occurs much more frequently in twin and triplet pregnancies
than in singleton pregnancies (32). Indeed, of the 64 multiple-
gestations families (63 twins, 1 triplet), 50 (78%) were PTB (in-
cluding EPTB and VEPTB; Fig. 3A). To assess the statistical
significance of the PTB-associated genomic variants when ex-
cluding the effect of multiple-gestation pregnancies, we removed
the 64 families with twins and triplets from our study cohort and
repeated the same statistical tests. We observed that associations
around the global threshold of 1 × 10−8 were quite variable, i.e., of
the 160 unique variants that were discovered using the complete
cohort, 71 (44%), were identified as statistically significant in the
single-gestation cohort. Conversely, 169 unique variants were
identified when excluding twin and triplet families that were not
significant previously (Fig. 3 B and C). Importantly, the variants
that were statistically most strongly related to PTB, i.e., P values
lower than 1 × 10−10 in the complete cohort, were identified at a
similar level of statistical significance for the single-gestation co-
hort (Fig. 3C). None of these variants were paternal. Related,
significant paternal variants showed the smallest agreement be-
tween the complete and single-gestation cohort (Fig. 3B). Overall,
we observed more variants that were significantly related to PTB-
related phenotypes in the single-gestation cohort (Fig. 3 B and C
and Dataset S9), including maternal variants in EBF1 and WNT4,
two of the six genes identified by Zhang et al. (22), associated
with VEPTB at the less stringent statistical threshold of FDR <
10%. However, the P values were not substantially lower for the
strongest associations compared with the complete cohort. The
largest number of associations was detected for the phenotypes
with the smallest number of cases, i.e., VEPTB, preeclampsia, and
uterine-related (Fig. 3B and Table 1). For the single-gestation cohort,
the number of cases is even smaller, leading to slightly more biased
P values and potentially more false-positive findings (SI Appendix,
Figs. S4 and S5).
Integrative Analysis Highlights Known and PTB Genes and Pathways.
We performed an integrative analysis of WGS, mRNA, miRNA,
and DNA methylation data from samples of maternal blood
drawn after birth. For this analysis, we used maternal samples
from the complete cohort, i.e., including multiple-gestation fami-
lies. mRNA, miRNA, and DNA methylation measurements were
all obtained from maternal whole blood samples. Totals of 684
RNA-seq and 766 miRNA samples were sequenced on an Illumina
HiSeq2000 system. We identified miRNA targets with multiMiR
(33). A total of 784 DNA methylation samples were analyzed on
the IlluminaMethylation 450K platform by using probes previously
identified as high in quality (34). All four data types (WGS, RNA-
seq, miRNA, and DNA methylation) were obtained for 629 fami-
lies. For the majority of mothers (71%), whole blood samples were
taken 1 d after birth. For 93% of the mothers, blood was drawn
within the first 4 d after birth. Molecular data derived from samples
taken more than 4 d after birth were not used in further analyses.
Fig. 1B shows an overview of the samples in this study.
We developed a unified workflow for the identification of
significant differences in the levels of expression or methylation
by using a generalized linear model framework (35). Age, ad-
mixture, and blood draw dates (as integers with day of birth as
zero) were used as covariates in the analysis (SI Appendix). We
identified known PTB genes from the literature (Dataset S4) and
used the hypergeometric test to test significance of overlap be-
tween gene lists (i.e., those newly identified in our work compared
with existing lists). For the expression and methylation quantitative
trait loci (QTL) analyses, we used MatrixEQTL (36) to identify genes
and methylation probes that were within (or overlapped with)
candidate genes. Covariates included maternal age, admixture
coefficients, and blood draw date.
We observed differential gene expression and DNA methyl-
ation across five phenotypes studied (Table 2 and Datasets S2,
S10, and S11), including our primary PTB phenotype, as well as
EPTB, VEPTB, preeclampsia, and idiopathic PTB. There were
215 differentially expressed genes (DEGs) and two differentially
methylated probes (DMPs) between PTB and FTB. There were
even more differences between FTB and each of the two more
extreme gestational age phenotypes: 650 DEGs and 273 DMPs
for EPTB and 838 DEGs and 811 DMPs for VEPTB. We did not
identify any significantly differentially expressed miRNAs. Dif-
ferentially expressed miRNAs have been reported in gestational
tissues such as cervix and placenta (37–39). However, we found
that this observation does not extend to peripheral blood, similar
to findings by Elovitz et al. (40).
Enrichment tests showed overlaps between the DEGs and
DMPs and previously reported PTB genes we obtained from a
variety of metastudies and databases (Dataset S4). Specifically,
DEGs from PTB, EPTB, and VEPTB were strongly enriched
in the Database for Preterm Birth (dbPTB) (41) (P = 6.2 × 10−4,
P = 7.7 × 10−15, and P = 8.0 × 10−12, respectively; Table 2 and
Dataset S5) as well as the genes reported in the work of McElroy
Table 2. Summary of genomic and molecular associations across clinical phenotypes
Clinical phenotype
Genomic Molecular
FBAT EIGENSTRAT DNA methylation mRNA miRNA
Family trio Maternal Union of FBAT and EIGENSTRAT Maternal
No. of variants No. of variants No. of genes No. of probes No. of genes No. of genes No. of miRNAs
PTB — — — 2 2 215*,†,‡ —
EPTB 3 42 7 273 258* 650*,†,‡,§ —
VEPTB 7 960 217*,†,§ 811 735 838*,†,‡ —
PROM 23 3 12 — — — —
Pre-eclampsia 78 1046 312*,§ — — 8 —
Idiopathic PTB 1 10 3 11 11 17 —
Placenta-related 13 — 10 — — — —
Uterine-related 105 276 132§ — — — —
Cervix-related 28 16 18 — — — —
Overview of statistically significant genomic associations (FDR <10%) and differentially expressed [FDR <10% and absolute log2(FC) >0.5] and
methylated genes (FDR <10%) between cases and controls for each phenotype.
*Statistically significant overlap with gene lists from dbPTB (41).
†Statistically significant overlap with candidate PTB genes (McElroy_PTB, ref. 19).
‡Statistically significant overlap with Pre-Eclampsia SNP Resource (59).
§Statistically significant overlap with genes involved in human birth timing (Plunkett_HBT, ref. 60).
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et al. (19) (P = 2.4 × 10−3, P = 2.1 × 10−7, and P = 3.0 × 10−8,
respectively). For VEPTB, we also detected significant overlap
between the DEGs and DMPs (P = 4.2 × 10−4; Dataset S5). The
substantial overlap between our results and those already pub-
lished demonstrate the value of integrating the genomic and
molecular data in this cohort, even though the previously
reported PTB genes were obtained from studies with quite dif-
ferent experimental setups and analyses.
Of all phenotypes tested, we observed a large number of associ-
ated variants, DEGs, and DMPs in only VEPTB (Table 2). To
further study VEPTB, we created a set of 72 “VEPTB genes”
(Dataset S12). These genes had a strong genomic association with
the VEPTB phenotype or were associated with VEPTB in at least
two of the three data types (WGS, DNA methylation, mRNA ex-
pression). Of these, 16 genes (TNR, MACC1, CSGALNACT1,
TRAPPC9, VAV2, HTR3A, MSI2, FOXK2, ALPL, SLC22A15,
GRB10, SBF2, CD163, CCBE1, ID3, and MAFB) had variants
significantly associated with VEPTB and were differentially meth-
ylated or differentially expressed (Fig. 4A). In particular, these
16 are not in dbPTB and therefore represent implicated genes. Only
three VEPTB candidate genes are found in dbPTB (IL10, FGD4,
and STAT5B). When looking across all PTB-related gene sets
(Dataset S4), 92% (66 of 72) of the VEPTB candidate genes have
not been previously reported to be associated with PTB. Of the six
previously reported genes, IL-10 was the most commonly reported
(five of seven gene sets), followed by TNR and TIMP2 (two of
seven gene sets). Two genes, RAB31 and RBPJ, had significant
associations found for all three data types (WGS, DNA methyl-
ation, and mRNA expression). A variant at chr18:9,761,389
(rs117652912) in an intron of RAB31 was present in mothers from
European and mixed ancestry (Fig. 4B). RAB31 is a member of the
RAS oncogene family coding for a small GTPase-binding protein
involved in vesicle and granule targeting (42). RAB31 is up-
regulated at term relative to midgestation (43) and has been impli-
cated in a GWAS of placental abruption (44). (In this study, variants
in RAB31 were not significantly associated with the placenta-related
phenotype.) A variant in RBPJ at chr4:26,343,502 was found asso-
ciated with VEPTB in the American and mixed populations (Fig.
4B). RBPJ is up-regulated and hypermethylated in VEPTB. RBPJ is
a transcriptional regulator in the Notch signaling pathway (45).
Heterozygous mutations in RBPJ, resulting in impaired DNA
binding of the encoded protein, are one of the causes of the rare
developmental disorder Adams–Oliver syndrome, which can involve
dermatologic, limb, and vascular anomalies (46).
As further supporting evidence for these VEPTB genes, we
observed within the validation cohort more variants in and around
the 72 VEPTB genes that were statistically associated with PTB,
EPTB, or VEPTB than in a comparable randomly selected set of
72 genes (SI Appendix, Supplementary Note 1).
To determine whether our identified genomic variants are re-
sponsible for differential expression and/or methylation, we per-
formed cis-expression QTL (eQTL) and cis-methylation QTL
(mQTL) analysis for all 72 VEPTB candidate genes. Specifically,
we performed the e/mQTL analysis by associating any variant with
aMAF> 1% in or near each of the VEPTB genes with the expression
and methylation levels of that gene. We found 2,328 eQTL and
403 mQTL pairs at an FDR < 10% (Dataset S13). These pairs pro-
vide evidence that these genomic variations may influence expression
of these nearby genes. However, we identified only one significant
eQTL relationship for a variant (chr20:1,825,838, rs73584704) that was
itself statistically associated with the VEPTB phenotype. This variant
was correlated with the expression of SIRPA (SI Appendix, Fig. S6).
PTB is thought to result from aberrations in systems such as
inflammatory, immune-related, and hormone regulation path-
ways (47). We used ConsensusPathDB (48), an interaction da-
tabase that integrates multiple public resources, to determine
whether the VEPTB candidate genes are enriched in particular
pathways. Our results indicate that VEPTB candidate genes are
involved in systems including EGFR (q-value 2.4 × 10−4) and
prolactin signaling pathways (q-value 2.4 × 10−4), inflammation-
and immunity-related pathways such as the IL-6 pathway (q-value
0.030), chemokine signaling (q-value 0.018), IFN-γ signaling
(q-value 0.024), and Notch1 signaling (q-value 0.029; Fig. 4C, SI
Appendix, Fig. S7, and Dataset S14). Although only 3 of the 72
VEPTB genes were previously implicated in PTB, the identified
pathways included many pathways that were previously associ-
ated with PTB. For example, the IL-6 signaling pathway and
inflammation-related processes have been previously implicated in
PTB (49–52). Analysis of GWAS data also implicated the RAS
pathway, which is downstream of EGFR (and part of the MAPK/
ERK pathway) with PTB (53). Notch signaling pathways, which
have a role in innate and adaptive immunity, were significantly
perturbed in our results and have recently been linked to PTB in
mouse models (54).
To further validate the association between VEPTB and these
pathways, we performed additional analyses of the genes in these
pathways, excluding, however, the 72 VEPTB genes that were used
to identify them. Specifically, we looked for association between
VEPTB and these pathways outside of the identified 72 VEPTB
genes. For this analysis, we defined a set of 1,324 “VEPTB pathway
genes” across 27 enriched pathways. Reexamination of the genomic
data showed a statistically significant enrichment of variants in or
around these VEPTB pathway genes that were associated with
VEPTB. Finally, we trained random forest machine learning models
to predict VEPTB status by using the gene-expression and DNA
methylation data for all genes in the associated pathways, excluding
the 72 VEPTB genes. The machine learning analyses showed that
VEPTB status could be predicted by the VEPTB pathway genes
with similar accuracy compared with the original 72 VEPTB genes,
and, in both cases, much better than with random gene sets (Fig.
4D, SI Appendix, Fig. S8, and Dataset S15). Detailed results of the
analyses on the VEPTB pathways are presented in SI Appendix,
Supplementary Note 2.
Discussion
We have described a study of PTB using a cohort of 791 family
trios from various ancestries, of which 270 had PTB. We obtained
and integrated WGS data from the fathers, mothers, and new-
borns in these family trios and RNA-seq gene expression and
DNA methylation data from maternal blood samples and gath-
ered comprehensive clinical information concerning pregnancy,
delivery, and newborn health. By using these clinical data, we
nonexclusively assigned the family trios into clinical groups that
are likely to have different molecular causes underlying PTB.
These groups included three based on gestational age, delineating
PTB (<37 wk; n = 270), EPTB (<34 wk; n = 117), VEPTB
(<28 wk; n = 44), and known clinical antecedents of PTB, such as
PROM and structural issues with the placenta, uterus, or cervix.
Stratification of the cohort in case and control sets for each of the
PTB-related clinical phenotypes enabled the discovery of genomic
and molecular correlates that were specific to phenotypes across
our heterogeneous cohort.
By using genomic statistical tests, we identified many variants
that were associated with the various PTB-related phenotypes,
albeit at moderate levels of statistical significance. Although we
found genes previously implicated in PTB, many previously
identified genes were not retrieved by our analyses. For example,
our study did not replicate the findings by Zhang et al. (22) at
the genome-wide significance level of 10−8, although, at a less
stringent statistical threshold, i.e., FDR < 10%, we did identify
four of the six genes described by Zhang et al. (22), albeit in
different SNPs (loci) associated with these genes. This could be
explained in part by our relatively lower sample count and eth-
nically diverse cohort. In general, published PTB association
studies report different variants and genes. Differences in study
design, cohort definition, and statistical data-analysis methods
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Fig. 4. Integrative analysis of genomic and molecular data for VEPTB families uncovers candidate genes. (A) Venn diagram of the overlap between genes
with significant variants associated with VETPB and differentially expressed and methylated genes. * Indicates statistically significant overlap between gene
sets (hypergeometric test P < 0.05). (B) Heatmaps depicting the distribution of variants in RAB31 (Upper Left) and RBPJ (Upper Right) across different ancestries for
FTB and VEPTB mothers. In each heat map panel, the ratio is the number of mothers who have the minor allele (homozygous or heterozygous) over the total
number of mothers from that ancestry group. Ancestries are represented by using the 1000 Genomes super populations notation. (Lower) Violin plots of dif-
ferential gene expression (Left) and differential DNA methylation (Right) of RAB31 between FTB and VEPTB. (C) Overview of pathways that were significantly
enriched with genes in the VEPTB candidate list of 72 genes. This overview is a selection of all significant pathways (listed in Dataset S14). The selection was
performed manually with the goal of including pathways related to immune and growth factor signaling, which formed the large majority of the enriched
pathways, yet avoiding redundancy among the selected pathways, i.e., excluding pathways with similar names and gene membership. (D) Mean area under the curve
(AUC) and associated interquartile range of VEPTB class prediction using a random forest classifier with different data types including RNA-seq data, DNA methylation
data, and a joint set of RNA-seq and methylation data. Prediction was performed with the 72 VEPTB genes (candidate); the 1,324 VEPTB pathway genes, i.e., the full
set of genes in associated pathways excluding the 72 VEPTB genes (pathway genes); and on each candidate pathway individually (one example shown, i.e., the
Notch1 pathway). Sets of random genes with identical set sizes are shown for comparison. Each mean AUC was computed by using cross-validation on a test set.
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certainly play a role in explaining this lack of agreement among
the various studies. We further evaluated the uncovered genomic
associations in two ways, first by removing families with twins and
triplets and second by employing an independent validation cohort
of more than 1,300 family trios. Exclusion of multiple-gestation
pregnancies, a well-known risk factor for PTB, may lead to a
“cleaner” study design. Indeed, we identified more significant
variants when using the single-gestation cohort, although these
associations were not stronger than those found by using the
complete cohort. Further, the most significant variants identified
in the complete cohort were also found when families with twins
and triplets were removed. In the validation cohort, we were able
to reproduce a small number of variants. Our validation exercises
may be considered as partially successful, as individual variants
were hard to reproduce. More large-scale genetic association
studies with deep clinical phenotypic data will be required to fully
ascertain the genomic contribution of this multifactorial syndrome.
By using an integrative approach whereby we combined theWGS
data with RNA-seq gene expression and DNA methylation data
from maternal blood samples, we identified PTB genes and path-
ways. Specifically for VEPTB, we uncovered various significantly
associated variants as well as differentially expressed and methylated
genes, many of which are involved in growth factor signaling and
inflammation- and immunity-related pathways. The finding that
inflammatory pathways are significant is not unexpected based on
previous biomarker studies, but our comprehensive approach with
the use of WGS, RNA-seq, and methylation data provides speci-
ficity in terms of gene involvement and suggests generalizability.
Implicated genes included RAB31 and RBPJ, members of the RAS
oncogene family and Notch signaling pathway, respectively, which
had significant associations found for all three data types. VEPTB is
associated with higher risks of infant death and disabilities. There-
fore, our identification of genes and pathways for VEPTB may be
of particular clinical relevance. In addition, dissecting the causes
of VEPTB may provide a window to a more broad understand-
ing of PTB. Interestingly, the genes identified in this study showed
marginal overlap with published biomarkers for PTB (SI Appendix,
Supplementary Note 3). This implies that our study potentially
identified PTB-related associations or biomarkers. Our observations
could also be explained, at least in part, by inconsistent reports of
genetic associations within this heterogeneously defined phenotype
of PTB-like syndromes. On the functional level of biological path-
ways, we found a greater agreement of our primary results with
published literature and within the validation cohort. Twenty of the
VEPTB genes we uncovered, as well as the previously known genes,
are involved in the immune response, inflammation, and growth
factor signaling pathways. Integrative analysis with gene expression
and DNA methylation data strengthened these findings. The ex-
pression and methylation data were derived from maternal blood
samples taken after birth, and may not be useful as predictors of
PTB. Specifically, samples taken in the immediate postpartum pe-
riod may reflect the transcriptomics of (preterm) labor rather than
the differences that are the underlying causes of PTB (55). Addi-
tional gene-expression data around the time of birth from placenta,
uterine tissue, and/or blood will be informative to further interpret
our results (11). Still, in our integrative approach, the molecular
data played an important role in implicating factors involved in the
biology of PTB. Importantly, the identified pathways, or gene signa-
tures derived from these pathways, may be more robust biomarkers
of VEPTB than individual genes or variants, and could be replicated
in future studies. Similar study designs would be useful in addressing
the limited published studies with multiomic characterization in
the same individuals, e.g., Eidem et al. (55) report that 18% of
published PTB-related studies include transcriptomic profiling.
The integration of other data types, such as from microbiome-based
studies as well as blood-based metabolites and proteins, could
also be an important adjunct to further analysis (56).
Our WGS focus allowed us to study rare variants. The impor-
tance of rare variants is likely to have been missed by previous
studies. Variants uncovered in GWAS studies are common variants,
generally with an MAF of at least 1%. In our primary analysis, we
focused on common variants; however, rare variants may play a
crucial role for complex diseases such as PTB (57). For example,
McElroy et al. (58) looked at rare variants in the context of PTB by
examining 10 exomes, including 2 mother–daughter pairs, and found
a potential link to the complement/coagulation factor pathway.
We also investigated rare variants in the set of 72 VEPTB genes
(SI Appendix, Supplementary Note 4 and Fig. S9 and Datasets
S16–S18). This analysis led to several moderately statistically sig-
nificant genes. The function of these genes and associations shown
in other studies suggests that they could play potential roles in PTB.
However, validation of these results will need to be carried out in
an independent cohort with a larger number of VEPTB samples.
The WGS data also enabled us to explore the relationship
between the prevalence of PTB with genetic risks of other dis-
eases through a comorbidity analysis by using published GWAS
markers for 56 common diseases. We observed that variation in
genetic risk varied substantially with ancestry, but not signifi-
cantly across PTB categories (SI Appendix, Supplementary Note 5
and Fig. S10 and Datasets S19 and S20).
Our study is an important step forward in understanding PTB
by using WGS-based clinical genomics. The comprehensive and
integrative approach we developed provided genomic information
at an unprecedented scale and resolution. This approach will aid
in the search for genetic contributors to the complex and het-
erogeneous condition of PTB. Such knowledge of the biology of
PTB should lead to better prediction and prevention.
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